Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18- 42 (upon starting COH);~* BMI \<30 kg/m2;~* \<3 prior ART cycles (IVF, ICSI and related procedures);~* Baseline (day 2-3 of cycling) FSH \<15 IU/L and E2 \<80 pg/mL;~* Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);~* At least 3 retrieved oocytes;~* Patient has given written informed consent.~Exclusion Criteria:~* Intramural uterine fibroids that distort the uterine cavity or polyps \>1 cm;~* Stage III or IV endometriosis (endometriomas);~* Hydrosalpinx;~* History of past poor response to COH resulting in canceling ART;~* Use of thawed/donated oocytes;~* Use of thawed/donated embryos;~* Patients affected by pathologies associated with any contraindication of being pregnant;~* Hypersensitivity to study medication;~* Uncontrolled adrenal or thyroid dysfunction;~* Undiagnosed vaginal bleeding;~* History of arterial disease;~* Patients with hepatic impairment;~* Neoplasias (current) or history of neoplasia that may be responsive to progesterone;~* High grade cervical dysplasia;~* Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders;~* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages wherein pregnancy developed to a minimum of a gestational sac on TVUS;~* Participation in a concurrent clinical trial or another trial within the past 2 months;~* Use of concomitant medications that might interfere with the study evaluation;~* Pre-implantation genetic diagnosis/screening.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone SC (Type: EXPERIMENTAL): None
- Progesterone Vaginal gel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).